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Abstract
Background: Postoperative  surveillance  after  curative
resection for colorectal cancer has been demostrated
to  improve  survival.  It  remains  unknown  however,
whether intensified surveillance provides a significant
benefit  regarding  outcome  and  survival.  this  study
was aimed at comparing different surveillance strate-
gies regarding their effect on long-term outcome.
Methods: Between 1990 and 2006, all curative resec-
tions  for  colorectal  cancer  were  selected  from  our
prospective  colorectal  cancer  database.  all  patients
were  offered  to  follow  our  institutionﾴs  surveillance
programm according to the asco guidelines. We de-
fined surveillance as “intensive” in cases where >70%
appointments  were  attended  and  the  program  was
completed. as “minimal” we defined surveillance with
<70% of the appointments attended and an incom-
plete program. as “none” we defined the group which
did not take part in any surveillance.
Results: out of 1469 patients 858 patients underwent
“intensive”,  297  “minimal”  and  314  “none”  surveil-
lance. the three groups were well balanced regarding
biographical data and tumor characteristics. the 5-year
survival rates were 79% (intensive), 76% (minimal) and
54%  (none)  (oR  1.480,  (95%  cI  1.135-1.929); 
p  <0.0001),  respectively.  the  10-year  survival  rates
were 65% (intensive), 50% (minimal) and 31% (none)
(p <0.0001), respectively. With a median follow-up of
70 months the median time of survival was 191 months
(intensive),  116  months  (minimal)  and  66  months
(none) (p <0.0001). after recurrence, the 5-year sur-
vival rates were 32% (intensive, p = 0.034), 13% (mini-
mal, p = 0.001) and 19% (none, p = 0.614). the medi-
an time of survival after recurrence was 31 months (in-
tensive, p <0.0001), 21 months (minimal, p <0.0001)
and 16 month (none, p <0.0001) respectively. 
Conclusion: Intensive surveillance after curative resec-
tion of colorectal cancer improves survival. In cases of
recurrent disease, intensive surveillance has a positive
impact on patients’ prognosis. large randomized, mul-
ticenter trials are needed to substantiate these results.
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IntRoductIon
colorectal  cancer  (cRc)  constitutes  the  third  most
common cause of cancer death in the us [1]. In Eu-
rope, there are more than 350 000 new cases each year
[2].  despite  advances  in  treatment  regimes,  at  least
40% of patients with uIcc stage II or III disease will
experience local or distant recurrence [3]. the purpose
of surveillance following curative therapy of colorec-
tal cancer is early identification of recurrent disease
which can potentially be cured by further surgical in-
terventions. 
the  assumption  that  early  detection  of  recurrent
disease leads to better outcome has been fortified by
several studies [4-7]. Meta-analyses showed a modest
but significant survival benefit for patients monitored
by an intensive surveillance program after resection of
cRc [8-11]. additional surgery can cure some patients
who  have  limited  local  recurrence  or  distant  metas-
tases, thus emphasising the importance of surveillance
after colorectal cancer surgery.
the guidelines for surveillance are a matter of con-
stant debate. In 2005, the american society of clinical
oncology (asco) revised the 2000 guidelines for sur-
veillance based on recent studies and reviews [12, 13].
nevertheless, it remains controversial which diagnos-
tic tests should be performed at what point of a sur-
veillance  program,  underlining  the  need  for  further
studies. 
Recently, we published the results of a prospective
analysis  for  patients  undergoing  a  surveillance  pro-
gram  following  surgical  resection  for  cRc  between
1979 and 1990 [14, 15]. We were now able to analyze
almost  1600  patients  who  received  curative  surgical
therapy throughout the period between 1990 and 2006
with regard to differences in prognosis correlated to
the intensity of the surveillance program. the purpose
of this prospective analysis was to evaluate whether an
intensive  surveillance  program  is  beneficial  for  pa-
tients after resection for cRc.
MatERIal and MEtHods
Between  January  1990  and  december  2006  we  per-
formed 2079 resections on patients with cRc at the
department of surgery, university of schleswig-Hol-
stein, campus l￼beck, germany. all data concerning
patients undergoing a colorectal resection at our insti-
tution are prospectively collected in a “colorectal can-
cer” database. We performed surveillance according to
asco guidelines [12, 13]. at the time of discharge all
patients were informed about the necessity for a regu-
lar  and  complete  postoperative  surveillance.  surveil-
lance  data  of  individual  patients  was  recorded  in  a
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4. Laubert_Umbruchvorlage  20.01.10  12:44  Seite 25standardized questionnaire for the first ten years after
resection.  thereafter,  the  responsible  physician  was
contacted and the questionnaire was sent to each pa-
tient on a yearly basis. If there was any missing data,
we addressed the registration office for residents for
support. 
We defined the surveillance as “intensive” in cases
where the participation was regular (>70% of the giv-
en appointments were attended) and the program was
completed. as “minimal” we defined surveillance with
less than 70% of the appointments attended and an
incomplete program. an incomplete program was de-
fined as a divergence between tests scheduled accord-
ing to the asco-guidelines and the testes actually ob-
tained. as “none” we defined cases which did not un-
dergo surveillance at all. consequently, we categorised
groups  of  patients  as  “intensive”,  “minimal”  and
“none”  surveillance.  Patients  presenting  with  rectal
and colon cancer simultaneously were defined as rectal
cancer patients. In this study, we compared the three
different groups with regard to local and distant recur-
rence, the rate of curative resection after recurrence
and the accordant 5- and 10-year survival rates. Recur-
rence was defined as the occurrence of a local (intra
and/or extramural) or distant tumor after curative re-
section (R0). only curative resections (R0) were identi-
fied from our database. Patients with R1 or R2 resec-
tion  as  well  as  patients  with  synchronous,  not  re-
sectable distant metastases were excluded. further ex-
clusion criteria were local excisions, inability to coop-
erate, ulcerative colitis- and crohnﾴs disease associated
cancer  and  hereditary  cancer  syndromes  (faP,  Hn-
Pcc).
statIstIcal analysIs
continuous variables were expressed as mean ﾱ stan-
dard deviation. the length of surveillance and follow-
up  was  expressed  as  median  and  range.  statistical
analysis was carried out univariately using the c2-test
and results were considered significant with p<0.05. a
p-value lower/less than 0.0001 was not calculated ex-
actly and is noted as p<0.0001. Probabilities of overall
survival rate were calculated according to the Kaplan-
Meier method. a log-Rank-test was applied for com-
parison with p<0.05 considered statistically significant.
starting time for survival analysis was the day of surgi-
cal resection of the primary colorectal cancer. Estima-
tions of the relative risk were expressed as odds ratio
(oR) with a 95% confidence interval (95% cI). all
calculations  were  performed  by  using  the  sPss  14
(sPss Inc, chicago, Il, usa) software.
REsults
Between 1990 and 2006, a total of 2079 patients un-
derwent surgery for cRc. subtracting the cases with
synchronous, not resectable distant metastases as well
as R1 and R2 resections, 1567 patients were operated
with curative intent. 
the in-hospital mortality rate was 4.4% (n = 69)
with a 30-day mortality rate of 3.9% (n = 61). another
29 patients (1.9%) died within the first three months
after surgery without any cause related to surgery or
tumor. this resulted in a total of 1469 patients who
were  potentially  available  for  surveillance  and  thus
constituted  the  study  population.  Within  this  group
793 (54%) primary tumors were located in the colon,
and  676  (46.0%)  in  the  rectum  including  20  (1.4%)
synchronous carcinomas. 
a total of 263 patients (17.9%) received a complete
regime of adjuvant chemo- or radiotherapy including
128/793  (16.1%)  patients  with  a  carcinoma  of  the
colon and 135/676 (20%) with a carcinoma of the rec-
tum. With 65.0% the main reasons not to complete or
begin an adjuvant therapy were refusal by the patients
and a decline in general condition. distribution among
the  groups  with  intensive,  minimal  and  none  was
equal.
out of 1469 patients, the majority underwent inten-
sive  surveillance  (n  =  858;  58.4%),  297  patients
(20.2%) underwent a minimal program (overall partici-
pation 78.6%). the group of patients not participating
in  surveillance  accounted  for  314  patients  (21.4%).
the groups of intensive, minimal and none surveil-
lance  were  well  balanced  regarding  stage  of  disease
and gender (table 1). notably, the cohort with none
surveillance was older and in a worse general condi-
tion. no patient was lost to follow-up.
suRvIval
the 5-year survival rates for the different groups were
79% (intensive), 76% (minimal) and 54% (none), re-
spectively. the inter-group comparison revealed a sta-
tistically significant improved overall survival for the
intensive  surveillance  group  (table  2;  intensive  vs.
minimal p<0.0001, intensive vs. none p<0.0001, mini-
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Table 1. Patientsﾴ clinical and biographical data.
Follow-up [median months] 70 (range 1 – 211)
Study population n = 1469
Surveillance intensive minimal none
n = 858 n = 297 n = 314
Gender
male 478 (56%) 150 (51%) 151 (48%)
female 380 (44%) 147 (49%) 163 (52%)
Age [years] 64,5 (ﾱ 10.9) 67,3 (ﾱ 11.5) 73,7 (ﾱ 11.6)
UICC-stage
stage I 293 (34%) 104 (35%) 102 (33%)
stage II 266 (31%) 95 (32%) 116 (37%)
stage III 273 (32%) 92 (31%) 92 (29%)
stage Iv 26 (3%) 6 (2%) 4 (1%)
Table 2. survival rates depending on the intensity of surveil-
lance.
Surveillance 5-year survival 10-year survival p-value
intensive 79% 65% <0.0001
minimal 76% 50% <0.0001
none 54% 31% <0.0001
4. Laubert_Umbruchvorlage  20.01.10  12:44  Seite 26mal vs. none p<0.0001). the 10-year survival rate for
the group with intensive surveillance was 65%, 50%
for the group with minimal surveillance and 31% for
the group with none surveillance (intensive vs. mini-
mal p <0.0001, intensive vs. none p <0.0001, minimal
vs. none p <0.0001; fig. 1).
after a median follow-up of 70 months the calcu-
lated median time of survival was 191 months (inten-
sive), 116 months (minimal) and 66 months (none), re-
spectively. the differences in the inter-group compari-
son were statistically significant (intensive vs. minimal
p <0.0001, intensive vs. none p <0.0001, minimal vs.
none p <0.0001) 
the odds ratio for a 5-year survival comparing in-
tensive  and  minimal  surveillance  was  1.480  (95%cI
1.135-1.929). the comparison of intensive and none
surveillance for a 5-year survival resulted in an odds
ratio of 2.606 (95% cI 1.983-3.425) (table 3). 
REcuRREncE
the overall rate of recurrence for both local and dis-
tant growth of tumor was 25.3% (n = 371). the 5-
year survival rates for patients with a recurrent disease
was 32% (intensive), 13% (minimal) and 19% (none),
respectively with statistically significant differences be-
tween the groups of; intensive and minimal (p = 0.034),
intensive and none (p <0.0001), but not between mini-
mal and. none (p = 0.614) surveillance (fig. 2).
the median time of survival after diagnosis of re-
current disease was 31 months (intensive), 21 months
(minimal) and 16 months (none), respectively (inten-
sive  vs.  minimal  p<0.0001,  intensive  vs.  none
p<0.0001, minimal vs. none p<0.0001).
Patients who appeared asymptomatic at the time of
diagnosis  of  recurrence  differed  among  the  groups.
out of the 243 patients with intensive surveillance 138
(56.8%) did not show symptoms of recurrence in con-
trast to 18 out of 49 patients (36.7%) with a minimal
program (p = 0.27). 
the odds ratio for a 3-year survival comparing in-
tensive and minimal surveillance was 1.917 (95% cI
1.007-3.651). the comparison of intensive and none
surveillance for a 3-year survival resulted in an odds
ratio of 2.434 (95%cI 1.088-5.448) (table 3). 
local REcuRREncE
local recurrence occurred in 5.1% (n = 75) (table 4).
Recurrence of colon cancer occurred in 2.9% (n = 23)
and recurrence of rectal cancer in 7.7% (n = 52). for
both the rectum and the colon an R0 resection of re-
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Fig. 1. survival after curative resection of colorectal cancer
depending on the intensity of surveillance.
Table 3. Relative Risk for 5-year survival after curative resec-
tion and for 3-year survival after diagnosis of recurrent dis-
ease.
Odds-ratio 95% confidence 
interval
5-year survival
Intensive vs. minimal 1.480 1.135-1.929
Intensive vs. none 2.606 1.983 – 3.425
3-year survival after
recurrence
Intensive vs. minimal 1.917 1.007-3.651
Intensive vs. none 2.434 1.088-5.448
Table 4. local Recurrence depending on site of primary tu-
mor.
Local recurrence total colon Rectum
total 75 (5.2%) 23 (2.9%) 52 (7.7%)
extramural 61 (4.2%) 20 (2,5%) 41 (6.3%)
intramural 14 (9.7%) 3 (0,4%) 11 (1.7%)
Fig. 2. survival after recurrent disease depending on the in-
tensity of surveillance prior to diagnosis.
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sive,  in  8%  (1/13)  for  minimal  and  25%  (3/12)  for
none surveillance, but failed to show statistically signif-
icant differences (intensive vs. minimal p = 0.126, in-
tensive vs. none p = 0.238, minimal vs. none p = 0.834).
the 5-year survival rate for patients who had an R0
resection of recurrent disease was 57% (fig. 3). the 5-
year survival rate was 11% for those patients who re-
ceived palliative surgical treatment and 0% for those
patients receiving other palliative means (curative vs.
palliative surgery p <0.0001, curative vs. other pallia-
tive means p <0.0001). for the group who did not re-
ceive any treatment the 5-year survival rate was also
0% (curative therapy vs. no therapy p <0.0001). the
median time of survival for the group with curative
treatment was 67 months, for the group with palliative
surgical therapy 11 months and in cases of other pal-
liative or without treatment the median time of sur-
vival was11 and 8 months, respectively.
dIstant MEtastasEs
a total of 241 patients (16.4%) presented with one or
more metastases. an R0 resection with regard to the
mode of surveillance was possible in 31.1% (50 /161)
of patients with intensive, in 19.4% (7/36) with mini-
mal and in 6.8% (3/44) with none surveillance (inten-
sive  vs.  minimal  p  =  0.165;  intensive  vs.  none  p  =
0.002, minimal vs. none p = 0.215).
the liver was the most common site for distant re-
currence  with  8.4%  (124)  of  all  patients  effected.
Metastases of the lung occurred in 5.4% (79) of the
total. In 7.6% (112) of all patients metastases were lo-
calized elsewhere.
Isolated liver metastases were detected in 5.2% (76)
of  patients  and  a  curative  resection  could  be  per-
formed in 40.8% (31). the 5-year survival rate after
curative surgery of isolated liver metastases was 47%
(median time of survival 57 months) in contrast to a
5-year survival rate of 0% (median time of survival 37
months)  for  palliative  resection  (p>0.05),  palliative
thermo ablation and palliative chemotherapy (median
time of survival 20 months, curative vs. non-surgical
palliative  means  p<0.0001).  the  5-year  survival  rate
for isolated liver metastases without any therapy was
also 0% (curative vs. none p<0.0001).
In 2.8% (41) of patients the lung was affected soli-
tarily. Here, a total of 46.4% (n = 19) could be resect-
ed  curatively.  after  curative  resection  of  isolated
metastases  of  the  lung,  the  5-year  survival  rate  was
66%, in contrast to a 5-year survival rate of 0% (medi-
an time of survival 23 months) for palliative surgery
(curative vs. palliative resection p = 0.125). other pal-
liative non-surgical means had a 5-year survival rate of
14% (median time of survival 17 months, curative vs.
other palliative means p = 0.002). the 5-year survival
rate for isolated lung metastases without any therapy
was also 0% (curative vs. none p <0.0001).
dIscussIon
since the introduction of surveillance after resection
for colorectal cancer there has been a constant debate
on how to practice follow-up [16-19]. several studies
have evaluated the effect of surveillance regarding out-
come  after  curative  resection.  a  significant  survival
benefit  from  intensive  postoperative  surveillance  has
been  shown  in  four  separate  meta-analyses  [8-11].
figuerdo et al. and Renehan et al. analyzed six and five
prospective,  randomized  trials,  respectively,  covering
1679 and 1342 patients [8, 10]. Renehan and colleagues
stated that intensive follow up may improve survival
because of earlier detection and treatment of recurrent
disease. they added that it may also be associated with
non-specific factors, such as a lesser psychological bur-
den in patients undergoing surveillance. the detection
rates in their meta-analysis for all local recurrences and
hepatic metastases were similar to those quoted in the
other studies. However, intensive follow-up was associ-
ated with a reduced time to first relapse and increased
detection of  isolated local recurrences [10].
tjandra  et  al.  presented  a  meta-analysis  of  eight
randomized clinical trials with 2923 patients included.
In this expanded systematic review they could confirm
– consistent with five previous meta-analyses – a re-
duction of mortality and an improvement in curative
reoperation rate with more intensive surveillance. of
the eight prospective trials, the largest study was the
large-scale  multicenter  European  study  gIlda
(gruppo Italian di lavoro per la diagnosi anticipata),
which had enrolled a total of 985 patients. this trial
was conducted to provide the first evidence, based on
an adequately powered randomized trial to determine
the  optimal  follow-up  strategy  for  colorectal  cancer
patients.  Recruitment  in  the  us  still  continues  and
therefore, however, the duration of follow-up was rel-
atively short at 14 months and data on longer-term
surveillance limited [11, 20]. In contrast to the results
obtained in these meta-analyses, only two of the eight
randomized  studies  suggested  a  significant  improve-
ment in survival for those undergoing intensive sur-
veillance [5, 7, 17, 20-25].
the few retrospective studies available are very het-
erogenous regarding the size of the cohorts, the pa-
tients’ characteristics and the time of follow-up [26-
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Fig. 3. survival after local recurrence depending on the mode
of therapy.
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which has been the largest retrospective study on this
matter [26]. they reported a significantly higher rate
of resect  able recurrent disease anda nimprovement in
sur  vival after curative resection of recurrent disease in
patients who underwent intensive follow-up. castells et
al. presented similar results in their study of 199 pa-
tients [27].
another prospective, randomized study stated a sig-
nificant difference in survival depending on the inten-
sity of surveillance only for patients with stage II dis-
ease and rectal tumors [7]. the results of this random-
ized controlled trial suggest that, although no differ-
ence on overall survival was observed in the whole se-
ries, patients with colorectal cancer who have under-
gone curative resection may benefit from a more in-
tensive  surveillance  strategy.  this  assumption  was
based on the fact that the intensive strategy increased
the proportion of resectable tumor recurrences in the
whole series as well as in some subsets of patients;
more importantly, it increased the probability of over-
all survival in patients with stage II lesions or rectal tu-
mors[7]. In contrast, Komborozos et al. could not re-
veal a difference in neither the rate of R0-resection
rate for recurrent disease nor the overall rate of sur-
vival after surgical treatment of recurrence [29].
our  analysis  of  prospective,  not  randomized  data
supports the view that intensive surveillance implies a
benefit in outcome. We were able to demonstrate a sig-
nificant difference in overall survival with a benefit for
patients  who  undergo  intensive  surveillance.  the  in-
creasing difference in the 5-year survival rate following
primary surgery depending on the intensity of surveil-
lance emphasizes the importance to encourage patients
to participate in such programs. our results are based
on data retrieved from a follow-up, which in median
was 70 months, a much longer period than that of most
other studies. In addition, with 1469 patients included,
we were able to analyze a cohort much larger than in
other trials, both prospective and restrospective.
In the present analysis, the overall rate of local re-
currence was significantly lower than the rate reported
in 24 independent studies that were reviewed by ohls-
son and P￥lsson [24]. We noted a rate of 5% in our
collective compared to a median rate of 13% (range of
5 to 23%) in this meta-analysis.
the results of our study show a significant improve-
ment in survival for patients who underwent intensive
surveillance prior to the diagnosis of a recurrent dis-
ease. notably, only intensive surveillance improved sur-
vival for the group of patients with a recurrent tumor.
Minimal surveillance had a similarly low effect on sur-
vival as none surveillance. In parallel, a meta-analysis
by Renehan and colleagues revealed that intensive fol-
low-up was associated with a significantly earlier detec-
tion of all recurrences. However, the rate of R0-resec-
tions for recurrent disease were not evaluated [10].
other studies were able to show a significant im-
provement in R0 resection rates for the group that un-
derwent intensive surveillance [7]. However, despite the
higher rates of R0 resections – contrary to our results
– the data of this multicenter, randomized trial did not
show a benefit in survival for patients undergoing in-
tensive surveillance prior to a recurrent disease [7].
the data presented suggest that the higher rate of
R0 resections of a recurrent disease contributes to the
significantly  improved  survival.  However,  the  differ-
ences in R0 resection rate of local recurrence were not
statistically significant comparing the groups with in-
tensive, minimal and none surveillance. the reason for
the lack of significance becomes obvious if one con-
siders  the  small  number  of  patients  in  the  distinct
groups, especially the one with none surveillance. 
the survival after resection of a recurrent disease
was significantly improved for the group with inten-
sive surveillance. However, with regard to the lack of
significance due to the small number of patients we
cannot comment on a possible difference in R0-resec-
tion rates for recurrent disease and an according im-
provement of survival between the groups that under-
went minimal and none surveillance. In contrast, the
differences in R0 resection rates for distant metastases
differed significantly and thus contributed to the im-
proved survival. 
our results are based on surveillance according to
the asco guidelines, where chest X-ray was recom-
mended on a regular basis. the modifications of 2005
imply a ct-scan of the abdomen and the thorax to be
performed annually in cases of colorectal cancer with
a  higher  risk  of  recurrence  [13].  consequently,  this
might lead to a higher percentage of detected recur-
rences which are eligible for R0-resection. However,
Rodriguez-Moranta  et  al.  performed  ct-scans  on  a
regular basis and could demonstrate a benefit in sur-
vival for the group with intensive surveillance for stage
II disease but not for stage III disease [7]. In addition,
they were able to show a benefit for those with a pri-
mary tumor located in the rectum but not for those
with a primary located in the colon. generally, the use
of ct-imaging in surveillance is performed irregularly
among the different studies which makes a compari-
son somewhat difficult [5, 7, 27].
the  data  presented  should  emphasize  the  impor-
tance to continue evaluations on the field of postoper-
ative  surveillance  after  primary  resection  for  cRc.
this includes the analysis of a definite improvement
in survival due to a correctly adapted surveillance pro-
gram and identification of patients who profit from
another resection of a recurrent tumor and/or metas-
tases. furthermore, consideration of the psychological
burden, which each surveillance appointment implies,
and improvement in costs resulting from a correctly
devised  program  remain  important  issues  to  be  ap-
proached on this matter. together with a modification
of surgical techniques, adjuvant therapy and the intro-
duction of other biochemical markers, it seems proba-
ble that given recommendations for surveillance will
constantly have to be reviewed and modified. 
conclusIon
the results of the study presented indicate a signifi-
cantly improved survival for patients who undergo a
systematic  and  intensified  surveillance  after  curative
resection of colorectal cancer. although we need an
ongoing debate on how to devise the ideal program of
surveillance after curative resection for colorectal can-
cer we could show a benefit in overall survival and in
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4. Laubert_Umbruchvorlage  20.01.10  12:44  Seite 29survival after resection of recurrent disease for those
patients who undergo intensive surveillance according
to the asco guidelines.
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